Tetanus Toxoid

CHEMBL2108875 Phase 4 ได้รับการอนุมัติ Vaccine component
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Tetanus toxoid is a vaccine component prepared by formaldehyde inactivation of tetanus neurotoxin (TeNT) from Clostridium tetani, which when administered as part of immunization schedules (DTaP, Td, Tdap), stimulates production of specific neutralizing antibodies that prevent the neurotoxin from binding to nerve terminals and blocking inhibitory neurotransmitter release. It forms the basis of universal tetanus immunization programs and is included in combination vaccines for pediatric and adult immunization. Booster doses maintain protective antibody levels throughout life.

ด้านการรักษา

กลไกการออกฤทธิ์

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Tetanus toxoid is a vaccine component prepared by formaldehyde inactivation of tetanus neurotoxin (TeNT) from Clostridium tetani, which when administered as part of immunization schedules (DTaP, Td, Tdap), stimulates production of specific neutralizing antibodies that prevent the neurotoxin from binding to nerve terminals and blocking inhibitory neurotransmitter release. It forms the basis of universal tetanus immunization programs and is included in combination vaccines for pediatric and adult immunization. Booster doses maintain protective antibody levels throughout life.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Tetanus Toxoid is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108875. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.